Recor Medical
Recor Medical raises $125M Series D at $400M valuation
Quick Facts
Recor Medical: Series D Funding Round
Recor Medical has successfully raised $125M in Series D funding, reaching a valuation of $400M.
Company Overview
Renal denervation system for hypertension
Funding Details
The Series D round was led by Deerfield Management, with participation from Boxer Capital, Cormorant Asset Management, Novo Holdings.
Company Information
- Headquarters: 125 Shoreway Road, San Carlos, CA 94070
- Founded: 2009
- Employees: 150+
- Category: MedTech
Investment
Recor Medical plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Deerfield Management: Verified investor in Series D
- Boxer Capital: Verified investor in Series D
- Cormorant Asset Management: Verified investor in Series D
- Novo Holdings: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
NeuroLink Brain Raises $580M Series D to Transform Healthcare
NeuroLink Brain secures $580M in Series D funding at $8.2B valuation to complete fda approval process, scale manufacturing for clinical deployment, and expand treatment applications.
MedTech Revolution Secures $890M Series D to Lead MedTech Innovation
MedTech Revolution raises $890M in Series D funding at $13.7B valuation to complete clinical trials for 5 medical devices, scale robotic surgery systems, and expand to asian markets.
ForSight Robotics raises $125M Series B at $700M valuation
ForSight Robotics raises $125M in Series B at $700M valuation. Ophthalmic surgical robots...